Search

Your search keyword '"Drandi, Daniela"' showing total 20 results

Search Constraints

Start Over You searched for: Author "Drandi, Daniela" Remove constraint Author: "Drandi, Daniela" Database Complementary Index Remove constraint Database: Complementary Index
20 results on '"Drandi, Daniela"'

Search Results

1. Molecular remission is an independent predictor of progression‐free survival in patients with Waldenström macroglobulinemia treated with chemo‐immunotherapy: Results from the FIL_BIOWM study.

2. S221: LONG‐TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)

3. Editorial: The emerging role of liquid biopsies in hematologic disorders.

4. Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma.

5. Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up.

6. Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights.

7. Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.

8. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.

9. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.

10. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.

11. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.

12. Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow‐up.

13. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients.

14. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.

15. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.

16. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia.

17. A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.

18. MicroRNAs regulate critical genes associated with multiple myeloma pathogeriesis.

19. High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.

20. Central Nervous System Relapse in a Patient with Mantle Cell Lymphoma in Continuous Clinical and...

Catalog

Books, media, physical & digital resources